[Voriconazole for the therapy of mycoses in recipients of solid organ transplants].
Invasive fungal infections (IFI) are the third cause of infectious complications in recipients of solid organ transplants (SOT), showing an incidence of 5-42% depending of the trasplanted organ. Moreover, IFI account for significant morbility and mortality in SOT, ranging between 25-95% depending on the type of fungus and its organ localization. Different strategies (prophylaxis, preemptive treatment, treatment, antifungal combinations, routes of administration) have been tested to improve the prognosis of IFI in SOT. To reach this objective, it was essential to have access to new antifungals showing a higher spectrum of activity on the fungal pathogens, both classical and emerging, and showing improvements in pharmacokinetic and pharmacodynamic characteristics, ease of administration and acceptability and lower rates of adverse effects. Introduction of voriconazole in the therapeutic arsenal has facilitated to reach these goals due to its special pharmacological characteristics, its in vitro antifungal activity and the in vivo clinical efficacy demonstrated in different studies.
Solé
Amparo
A
Unidad de Trasplante Pulmonar, Hospital Universitario La Fe, Valencia, Spain.
Salavert
Miguel
M
D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D016040:Lung Transplantation; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole